***Background.*** Asunaprevir (ASV) is a selective NS3 protease inhibitor with *in vitro* activity vs hepatitis C virus (HCV) GT 1, 4, 5 and 6. Methadone (MET) and buprenorphine (BUP) are opioid analgesics; patients on HCV therapy may also require MET or BUP to treat opioid dependence. The effect of ASV on MET or BUP/naloxone (NLX) pharmacokinetics (PK) was assessed in subjects on stable opioid therapy.

***Methods.*** An open-label, 2-part study assessed the effect of steady-state ASV on the PK of MET (Part 1, P1) or BUP/NLX (Part 2, P2). Safety/tolerability and pharmacodynamics (PD; opiate withdrawal scales/overdose assessment) were also assessed. Subjects (P1, N = 15; P2, N = 16) received once daily oral MET (40--120mg) or BUP/NLX (8/2--24/6mg) based on prescribed stable dose throughout, in addition to ASV (100 mg BID) on Days 2--12. Serial PK sampling occurred on Days 1 and 12 up to 24 hours postdose. Non-compartmental PK were derived. Ratios of geometric means (GMR) and 90% confidence intervals (90%CI) for R-MET/S-MET/BUP/norBUP C~max~ and AUC~TAU~ with and without ASV were derived from linear mixed effects model on log-transformed data.

***Results.*** Subjects were aged 20--53 years, mostly white (P1, 87%; P2, 100%) and male (P1, 67%; P2, 75%). All completed the study. No clinically meaningful effect was shown as GMR 90% CIs fell within pre-specified interval (P1, 0.7--1.4; P2, 0.5--2.0). ASV coadministration with MET or BUP/NLX was generally well tolerated (P1, 6 \[40%\] subjects had 9 generally mild AEs; P2, 7 \[44%\] subjects had AEs, all mild). ASV had no clinically meaningful effect on the PD of MET or BUP/NLX; 1 patient experienced moderate drug withdrawal syndrome but had mild withdrawal symptoms before the study, therefore the association is unclear.

                                 With ASV   W/O ASV   GMR
  ------------------------------ ---------- --------- ------------------
  **R-MET^a^ C~max~***, ng/mL*   116.2      120.2     0.97 (0.86,1.08)
  ** AUC~TAU~***, ng•h/mL*       1757.7     1924.2    0.91 (0.82,1.01)
  **BUP C~max~**                 4.5        5.3       0.85 (0.71,1.01)
  ** AUC~TAU~**                  36.1       37.1      0.97 (0.73,1.30)
  **NORBUP C~max~**              2.1        1.8       1.17 (0.96,1.42)
  ** AUC~TAU~**                  33.0       30.1      1.10 (0.72,1.68)

^a^S-MET and total MET results similar

Exposures were normalized to lowest dose of MET or BUP.

***Conclusion.*** Steady-state administration of ASV 100 mg BID had no clinically meaningful effect on the PK of MET or BUP/NLX and was generally well tolerated, suggesting that no dose adjustments are required.
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